Ningetinib not checked
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Stage IV Non-small Cell Lung Cancer, Advanced HCC
- Main trialPhase 2
- “This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.”In the company’s words, NCT03838848 on ClinicalTrials.gov
Other drugs for Stage IV Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 30 Jul 2022 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | |
| Phase 1/2Terminated | 30 May 2022 | KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026